Acceleron Pharma Inc. (XLRN)’s Financial Results Comparing With Evogene Ltd. (NASDAQ:EVGN)

Acceleron Pharma Inc. (NASDAQ:XLRN) and Evogene Ltd. (NASDAQ:EVGN) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Acceleron Pharma Inc. 44 0.00 45.40M -2.76 0.00
Evogene Ltd. 2 0.00 23.06M -0.74 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.


Table 2 hightlights the net margins, return on assets and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
Acceleron Pharma Inc. 102,924,506.91% -35.9% -33.4%
Evogene Ltd. 1,414,203,360.73% 0% 0%

Analyst Recommendations

Acceleron Pharma Inc. and Evogene Ltd. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Acceleron Pharma Inc. 0 2 2 2.50
Evogene Ltd. 0 0 0 0.00

Acceleron Pharma Inc.’s upside potential currently stands at 33.36% and an $52.25 consensus price target.

Insider & Institutional Ownership

Institutional investors owned 93.6% of Acceleron Pharma Inc. shares and 0% of Evogene Ltd. shares. 0.6% are Acceleron Pharma Inc.’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Acceleron Pharma Inc. 2.78% 3.39% 9.2% 4.8% 4% 0.25%
Evogene Ltd. 0.5% -11.14% -34.36% -28.56% -51.9% -26.4%

For the past year Acceleron Pharma Inc. has 0.25% stronger performance while Evogene Ltd. has -26.4% weaker performance.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases. Its therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases. The companyÂ’s therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy. It has collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Evogene Ltd., a biotechnology company, focuses on the enhancement of crop productivity and performance in the United States and Germany. It operates through two segments, Evogene and Evofuel. The Evogene segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. This segment develops seed traits enhancing plant yield and tolerance to abiotic stresses, such as enhanced tolerance to drought, heat, and salinity, as well as seed traits for enhancing plant resistance to biotic stresses, including resistance to diseases, pests, and insects; novel herbicides; and bio-stimulants, which include microbial-based products that are applied externally to the plant for yield enhancement. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Evofuel segment develops enhanced species of the castor bean plant to serve as a source of feedstock for biofuel and other industrial uses. The company has strategic collaborations with various agricultural companies, including BASF, Bayer, DuPont, Monsanto, and Syngenta that cover 24 products in various stages of development. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.